EyePoint raises ~$150M in public offering to fund DURAVYU clinical development

EyePoint, Inc.

Pricing: 11M shares at $12.00 each; 1.5M pre-funded warrants at $11.999 each.
Gross proceeds ~$150M; net proceeds after underwriting discounts ~$141M.
Net proceeds to advance DURAVYU for wet AMD and DME, plus pipeline and general purposes.
Underwriters have 30-day option for up to 1,875,000 additional shares at $12.00.
Offering closed on October 16, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.